Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Stock Position Raised by JPMorgan Chase & Co.

JPMorgan Chase & Co. increased its stake in shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) by 7,086.9% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 51,961 shares of the company's stock after purchasing an additional 51,238 shares during the quarter. JPMorgan Chase & Co. owned 0.20% of Eton Pharmaceuticals worth $692,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in the stock. Westside Investment Management Inc. raised its stake in shares of Eton Pharmaceuticals by 5.7% during the 3rd quarter. Westside Investment Management Inc. now owns 618,675 shares of the company's stock worth $3,711,000 after buying an additional 33,275 shares during the period. Geode Capital Management LLC lifted its holdings in Eton Pharmaceuticals by 13.5% in the 3rd quarter. Geode Capital Management LLC now owns 272,696 shares of the company's stock worth $1,637,000 after buying an additional 32,365 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its position in Eton Pharmaceuticals by 230.5% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 214,878 shares of the company's stock valued at $2,862,000 after purchasing an additional 149,864 shares during the period. Thompson Siegel & Walmsley LLC grew its stake in shares of Eton Pharmaceuticals by 11.3% in the 4th quarter. Thompson Siegel & Walmsley LLC now owns 128,039 shares of the company's stock worth $1,705,000 after purchasing an additional 13,009 shares during the last quarter. Finally, Anchor Capital Advisors LLC acquired a new position in Eton Pharmaceuticals in the 4th quarter worth about $805,000. Hedge funds and other institutional investors own 27.86% of the company's stock.

Eton Pharmaceuticals Stock Performance

NASDAQ:ETON traded up $0.37 during mid-day trading on Friday, hitting $17.34. 239,854 shares of the company's stock traded hands, compared to its average volume of 180,687. The company has a market capitalization of $465.02 million, a P/E ratio of -78.82 and a beta of 1.34. The company has a fifty day moving average of $14.28 and a 200 day moving average of $13.25. Eton Pharmaceuticals, Inc. has a twelve month low of $3.18 and a twelve month high of $18.41.

Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last posted its quarterly earnings results on Tuesday, March 18th. The company reported ($0.02) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.02). Eton Pharmaceuticals had a negative net margin of 15.81% and a negative return on equity of 36.29%. The firm had revenue of $11.65 million for the quarter, compared to analyst estimates of $10.53 million. On average, research analysts expect that Eton Pharmaceuticals, Inc. will post -0.14 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the stock. Craig Hallum upped their target price on shares of Eton Pharmaceuticals from $23.00 to $26.00 and gave the stock a "buy" rating in a research report on Wednesday, March 19th. HC Wainwright restated a "buy" rating and issued a $33.00 price objective on shares of Eton Pharmaceuticals in a report on Wednesday, March 19th. Finally, B. Riley reissued a "buy" rating and issued a $24.00 price target (up from $21.00) on shares of Eton Pharmaceuticals in a report on Wednesday, March 19th.

Eton Pharmaceuticals Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.